Oscar Health Revises 2025 Guidance: Projects Total Revenue Up to $12.2B, Reports Expected Net Loss of $228M for Q2

Reuters

07-22

Oscar Health Revises 2025 Guidance: Projects Total Revenue Up to $12.2B, Reports Expected Net Loss of $228M for <a href="https://laohu8.com/S/QTWO">Q2</a>

Oscar Health, Inc. announced preliminary financial results for the second quarter of 2025, reporting a loss from operations of approximately $230 million and a net loss of about $228 million. These figures are based on an analysis of 2025 Marketplace data from Wakely, an independent actuarial firm. The company has revised its full-year 2025 guidance, now anticipating total revenue between $12.0 billion and $12.2 billion. Oscar Health expects a Medical Loss Ratio ranging from 86.0% to 87.0% and a Selling, General and Administrative (SG&A) Expense Ratio between 17.1% and 17.6%. The anticipated loss from operations for the full year is estimated to be between $300 million and $200 million. Additionally, the company projects an Adjusted EBITDA loss approximately $120 million less than the loss from operations. Oscar Health is set to release its detailed second-quarter 2025 financial results on August 6, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oscar Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250722772545) on July 22, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2553234662"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2553234662\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2553234662?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-22 18:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2553234662","market":"fut","top_or_hot":-1,"title":"Oscar Health Revises 2025 Guidance: Projects Total Revenue Up to $12.2B, Reports Expected Net Loss of $228M for Q2","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Oscar Health Revises 2025 Guidance: Projects Total Revenue Up to $12.2B, Reports Expected Net Loss of $228M for <a href=\"https://laohu8.com/S/QTWO\">Q2</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/OSCR\">Oscar Health, Inc.</a> announced preliminary financial results for the second quarter of 2025, reporting a loss from operations of approximately $230 million and a net loss of about $228 million. These figures are based on an analysis of 2025 Marketplace data from Wakely, an independent actuarial firm. The company has revised its full-year 2025 guidance, now anticipating total revenue between $12.0 billion and $12.2 billion. Oscar Health expects a Medical Loss Ratio ranging from 86.0% to 87.0% and a Selling, General and Administrative (SG&amp;A) Expense Ratio between 17.1% and 17.6%. The anticipated loss from operations for the full year is estimated to be between $300 million and $200 million. Additionally, the company projects an Adjusted EBITDA loss approximately $120 million less than the loss from operations. Oscar Health is set to release its detailed second-quarter 2025 financial results on August 6, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oscar Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250722772545) on July 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oscar Health Revises 2025 Guidance: Projects Total Revenue Up to $12.2B, Reports Expected Net Loss of $228M for Q2</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOscar Health Revises 2025 Guidance: Projects Total Revenue Up to $12.2B, Reports Expected Net Loss of $228M for Q2\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-22 18:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Oscar Health Revises 2025 Guidance: Projects Total Revenue Up to $12.2B, Reports Expected Net Loss of $228M for <a href=\"https://laohu8.com/S/QTWO\">Q2</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/OSCR\">Oscar Health, Inc.</a> announced preliminary financial results for the second quarter of 2025, reporting a loss from operations of approximately $230 million and a net loss of about $228 million. These figures are based on an analysis of 2025 Marketplace data from Wakely, an independent actuarial firm. The company has revised its full-year 2025 guidance, now anticipating total revenue between $12.0 billion and $12.2 billion. Oscar Health expects a Medical Loss Ratio ranging from 86.0% to 87.0% and a Selling, General and Administrative (SG&amp;A) Expense Ratio between 17.1% and 17.6%. The anticipated loss from operations for the full year is estimated to be between $300 million and $200 million. Additionally, the company projects an Adjusted EBITDA loss approximately $120 million less than the loss from operations. Oscar Health is set to release its detailed second-quarter 2025 financial results on August 6, 2025.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oscar Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250722772545) on July 22, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"OSCR","symbol_name":"Oscar Health, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250722:nNDLb8CkcB:1","article_id":"2553234662","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2553234662","pubTimestamp":1753178441,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Oscar Health, Inc. announced preliminary financial results for the second quarter of 2025, reporting a loss from operations of approximately $230 million and a net loss of about $228 million. These figures are based on an analysis of 2025 Marketplace data from Wakely, an independent actuarial firm. The company has revised its full-year 2025 guidance, now anticipating total revenue between $12.0 billion and $12.2 billion. Oscar Health expects a Medical Loss Ratio ranging from 86.0% to 87.0% and a Selling, General and Administrative  Expense Ratio between 17.1% and 17.6%. The anticipated loss from operations for the full year is estimated to be between $300 million and $200 million. Additionally, the company projects an Adjusted EBITDA loss approximately $120 million less than the loss from operations. Oscar Health is set to release its detailed second-quarter 2025 financial results on August 6, 2025.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"OSCR":"Oscar Health, Inc."},"translate_title":"Oscar Health修订2025年指引：预计总收入高达$12.2 B，报告预计第二季度净亏损为$2.28亿","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OSCR":0.9},"content_text":"Oscar Health Revises 2025 Guidance: Projects Total Revenue Up to $12.2B, Reports Expected Net Loss of $228M for Q2\n\n\nOscar Health, Inc. announced preliminary financial results for the second quarter of 2025, reporting a loss from operations of approximately $230 million and a net loss of about $228 million. These figures are based on an analysis of 2025 Marketplace data from Wakely, an independent actuarial firm. The company has revised its full-year 2025 guidance, now anticipating total revenue between $12.0 billion and $12.2 billion. Oscar Health expects a Medical Loss Ratio ranging from 86.0% to 87.0% and a Selling, General and Administrative (SG&A) Expense Ratio between 17.1% and 17.6%. The anticipated loss from operations for the full year is estimated to be between $300 million and $200 million. Additionally, the company projects an Adjusted EBITDA loss approximately $120 million less than the loss from operations. Oscar Health is set to release its detailed second-quarter 2025 financial results on August 6, 2025.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oscar Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250722772545) on July 22, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}